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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative motor neuron (MN) disease. The gene encoding
superoxide dismutase 1 (SOD1) is a causative element of familial ALS. Animal ALS models involving SOD1 gene
mutations are widely used to study the underlyingmechanisms of disease and facilitate drug discovery. Unfortu-
nately, most drug candidates have failed in clinical trials, potentially due to species differences among rodents
and humans. It is unclear, however, whether there are different responses to drugs among the causative genes
of ALS or their associated mutations. In this study, to evaluate different SOD1 mutations, we generated SOD1-
ALS models derived from human embryonic stem cells with identical genetic backgrounds, except for the
overexpression of mutant variants of SOD1. The overexpression of mutant SOD1 did not affect pluripotency or
MN differentiation. However, mutation-dependent reductions in neurite length were observed in MNs.
Moreover, experiments investigating the effects of speciﬁc compounds revealed that each ALS model displayed
different responses with respect to MN neurite length. These results suggest that SOD1 mutations could be
classiﬁed based the response of MNs to drug treatment. This classiﬁcation could be useful for the development
of mutant-speciﬁc strategies for drug discovery and clinical trials.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease characterized by death of both upper and lower motor neurons
(MNs) (Beckman et al., 2001). About 90% of ALS cases are sporadic. The
remaining 10% of cases are classiﬁed as familial ALS (FALS), which is
characterized by mutations in genes including superoxide dismutase 1
(SOD1), transactive response DNA-binding protein 43 kDa (TARDBP,
TDP-43), fused in sarcoma (FUS) and chromosome 9 open reading
frame 72 (C9ORF72) (Rosen et al., 1993) (Neumann et al., 2006)
(Vance et al., 2009) (Renton et al., 2011). Approximately 20% of FALS
cases are caused by mutations in the SOD1 gene, and over a hundred
SOD1 mutations have been reported to date (Renton et al., 2014). The
average age at onset of SOD1-related ALS (SOD1-ALS) is 55 years; the
primary hallmark of both SOD1-ALS and other forms of the disease is
death of MNs leading to muscle weakness (Lyall et al., 2001)
(Millecamps et al., 2010) (Bruijn et al., 2004). Riluzole is the drug
approved for the treatment of ALS, and is effective in the extension of
the patient's lifetime for a relatively limited duration. Hence, there is a
great demand for more efﬁcacious drugs. Although many candidate
drugs for ALS have been discovered using animal models, almost all of
these drugs have failed clinical trials, potentially because of species
differences in drug responses among rodents and human beings
(Glicksman, 2011) (Limpert et al., 2013).
Human pluripotent stem cell (hPSCs)-based disease models are
promising tools to overcome the problems associated with species
differences. Recently, studies reported cellular ALS models that used
hPSCs including human embryonic stem cells (hESCs) and induced plu-
ripotent stem cell (iPSCs). Using thesemodels, MN deathwas observed,
indicating an ALS phenotype (Wada et al., 2012) (Bilican et al., 2012).
Additionally, new drug candidates, kenpaullone and anacardic acid
were discovered (Egawa et al., 2012; Yang et al., 2013). However,
because these models do not generally have an identical genetic
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background, it is difﬁcult to accurately compare results among the var-
ious mutations in ALS-related genes.
Here, to investigate the speciﬁc differences among SOD1 mutations,
we generated hESC-derived models of SOD1-ALS with identical genetic
backgrounds, except for those resulting in the overexpression of SOD1
variants. We found no differences in pluripotency or the ability to
differentiate into MNs among any of the SOD1-overexpressing hESCs
(SOD1-hESCs). Our cell model also demonstrated mutant-speciﬁc
phenotypes including mutant-dependent reduction in MN neurite
length. Additionally, using several compounds, we found that each
ALS model showed different responses to these compounds.
2. Materials and methods
2.1. Establishment of SOD1-overexpressing hESC lines
HESCs were cultured on mitomycin-C-treated mouse embryonic
ﬁbroblasts in primate ES medium (ReproCELL, Japan), supplemented
with 5 ng/mL ﬁbroblast growth factor 2 (Wako Chemicals, Japan), as
previously described (Suemori et al., 2006). To generate WT or mutant
SOD1 overexpressing hESCs, the site-speciﬁc gene integration method,
which we developed previously (Sakurai et al., 2010), was applied.
Both the SOD1 and Cre recombinase expression vectors were
introduced into the parental hESCs derived from the hESC line KhES-1
(Suemori et al., 2006). SOD1 cDNAs in the expression vector were
integrated into the HPRT1 locus on the genome of the parental hESCs.
Hygromycin-resistant clones, which showed normal cell growth, were
isolated and used as SOD1-overexpressing hESCs (SOD1-hESCs).
Karyotype analysis was carried out by Nihon Gene Research Laborato-
ries, Inc. The hESC lines were used in accordance with the Guidelines
for Derivation andUtilization of Human Embryonic StemCells proposed
by the Ministry of Education, Culture, Sports, Science, and Technology
(MEXT) of Japan.
2.2. Immunocytochemistry
Cells were ﬁxed in both 4% paraformaldehyde (Nacalai Tesque,
Japan) and 4% sucrose (Wako), and permeabilized using 0.2% Triton X-
100 (Nacalai Tesque, Japan). After blockingwith 1.5% bovine serum albu-
min at room temperature, cells were incubated with a primary antibody
overnight, followed by a secondary antibody for 1 h at 4 °C. The primary
antibodies used in this study were mouse anti-OCT3/4 monoclonal anti-
body (mAb) (Santa Cruz Biotechnology), rabbit anti-NANOG polyclonal
antibody (pAb; Cell Signaling Technology), mouse anti-SSEA4 mAb
(Millipore), mouse anti-TRA-1–60 mAb (Millipore), rabbit anti-nestin
pAb (Millipore), mouse anti-OLIG2 mAb (Millipore), mouse anti-ISL-1/
2 mAb (Developmental Studies Hybridoma Bank), mouse anti-MNR2
mAb (HB9, Developmental Studies Hybridoma Bank), mouse anti-TUJ1
mAb (Sigma-Aldrich), and rabbit anti-MAP2 pAb (Millipore). Secondary
antibodies used in this study were goat anti-mouse immunoglobulin-G
pAb conjugated with Alexa Fluor 488 or 546 (Molecular Probes), and
goat anti-rabbit immunoglobulin-G pAb conjugated with Alexa Fluor
488 or 546 (Molecular Probes). Cells were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) for visualization of all nuclei after the
treatment of secondary antibody. Image acquisition was performed
using an inverted Olympus IX71 epi-ﬂuorescence microscope with an
Olympus DP73 CCD camera (Olympus). Imageswere randomly captured
from more than six or ten ﬁelds per single experiment to calculate MN
differentiation rates or for measuring MN morphologies, respectively.
The neurite length and soma sizes of neuronsweremeasured by CellSens
Dimension software (Olympus).
2.3. Western blot analysis
Conﬂuent hESCs were dissolved with cold RIPA buffer (Sigma)
supplemented with halt protease and phosphatase inhibitor cocktail
(Thermo Scientiﬁc) and mixed using a vortex mixer. Lysates were cen-
trifuged at 12,000 rpm for 20 min at 4 °C and the supernatants were
used as protein samples. Protein concentrations were measured using
the Pierce BCA Protein Assay Kit (Thermo Scientiﬁc). Protein samples
were diluted with 4× Laemmli Sample Buffer (Bio Rad) and 2-
mercaptoethanol (Wako) and then boiled at 95 °C for 5 min. Samples
were electrophoresed through 4–20% precast gel (Cosmo Bio Co.,
Japan) with Tris/Glycine/SDS Buffer (Bio Rad), and then transferred to
polyvinylidene diﬂuoride membranes (Bio Rad) with Tris/Glycine
Buffer (Bio Rad). After treatment with Blocking One solution (Nacalai
Tesque), membranes were incubated with a primary antibody over-
night at 4 °C and then incubated with a secondary antibody for 1 h at
room temperature. To visualize proteins bonding with antibodies, the
Novex ECL HRP Chemiluminescent Substrate Reagent Kit (Invitrogen)
and the luminescent image analyzer LAS3000 (Fujiﬁlm) were used.
Quantiﬁcation of the band intensitywas performedbyMulti Gauge soft-
ware (Fujiﬁlm). The primary antibodies used in this study were rabbit
anti-superoxide dismutase1 pAb (Abcam), rabbit anti-superoxide
dismutase pAb (Stressgen), and mouse anti-β-actin mAb (Abcam).
The secondary antibodies used were anti-mouse IgG HRP-linked
antibody (Cell Signaling), goat anti-rabbit IgG HRP-linked antibody
(Santa Cruz).
2.4. Motor neuron differentiation
Two MN differentiation methods were carried out in this study
(Supplementary Fig. S2). The ﬁrst was our previous method with a
slight modiﬁcation (Wada et al., 2012; Wada et al., 2009) (Supplemen-
tary Fig. S2A). Brieﬂy, a bone morphogenetic protein inhibitor,
LDN193189 (200 nM; Cellagen Technology), was used as a neural in-
ducer (stage P1, shown in Supplementary Fig. S2A). In stage P2, cells
were treated with 200 nM LDN193189 and 100 nM all-trans retinoic
acid (ATRA; Sigma-Aldrich) in N2B27 neural differentiation medium
(NDM). Neural rosettes in the P2 cells were re-plated on poly-L-lysine/
laminin/ﬁbronectin (PLL/LM/FN)-coated culture dishes and cultured in
NDM supplemented with 2.5 μMATRA, 1 μMpurmorphamine (Cayman
Chemical), and 2.5 μMCHIR99021 (R&D). After 2 days, themediumwas
changed to NDM supplemented with 1 μMATRA, 1 μMpurmorphamine
(Tocris Bioscience), and 1 μM CHIR99021, and cells were cultured for
5 days. Then, the cells were cultured in NDM containing 10 ng/mL
brain-derived neurotrophic factor (BDNF; PeproTech), 10 ng/mL glial
cell-derived neurotrophic factor (GDNF; PeproTech), and 10 ng/mL
neurotrophin-3 (NT-3; PeproTech) for another 2 weeks.
The second differentiationmethodwas established in this study (Sup-
plementary Fig. S2B). For neural induction, dissociated ES colonies were
grown on PLL/LM-coated culture dishes in NDM supplemented with
200 nM LDN193189 and 1 μM SB431542 for 8 days (stage P1, shown in
Supplementary Fig. S2B). The medium was changed every other day.
Primary colonies were split into small groups of cells using 200 U/mL
collagenase with 1 mM CaCl2, plated on new PLL/LM-coated culture
dishes, and cultured in NDM supplemented with 200 nM LDN193189
(stage P2, shown in Supplementary Fig. S2B) for 8 days. Then, cells were
re-plated and cultured in NDM alone for 8 days. Neural rosettes formed
during the P3 stage. Neural rosettes were dissociated using Accutase
(Innovative Cell Technologies, Inc) and plated onto gelatin-coated culture
dishes for 45–60 min at 37 °C to remove non-neural cells. Unattached
cells were then cultured on PLL/LM/FN-coated culture dishes in NDM
supplemented with 0.5 μM ATRA, 0.5 μM purmorphamine, 0.5 μM
CHIR99021, 10 ng/mL BDNF, 10 ng/mL GDNF, and 10 ng/mL NT-3 for
7 days. For long-term culture in the P4 stage, cells were treated 1 μM
Cytarabine (AraC), and the medium was changed every 7 days.
2.5. Chemicals
Kenpaullone and riluzole were purchased from Cayman Chemical.
Y27632 and dbcAMP were purchased fromWako Chemicals. TRO19622
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were purchased from Sigma. MCI-186 was purchased from Focus
Biomolecules. The treatment with these chemicals was performed
from d3 to d7 (over a 4-day period) on cells in stage P4 (Supplementary
Fig. S2B). The chemical concentrations used in this study in Fig. 5 were
same as reported in previous studies exceptMCI-186 (Rojas et al., 2014)
(Bryan et al., 2006) (Gunther et al., 2014) (Yang et al., 2013) (Bordet
et al., 2007).
2.6. RNA isolation and PCR analysis
Total RNA was extracted using an RNeasy Kit (Qiagen), and cDNA
was synthesized using ReverTra Ace qPCR RT Master Mix (Toyobo,
Japan). PCR was performed using KOD FX (Toyobo, Japan) or TaKaRa
Ex Taq (TaKaRa, Japan). The primers used in this study are shown in
Supplementary Table S2.
2.7. SOD enzyme assay
The enzymatic activity of SODwasmeasured using an SODAssay kit-
WST (Dojindo Molecular Technologies Inc., Japan) according to
the manufacturer's protocol. In brief, hESCs were centrifuged at
12,000 rpm for 30 min at 4 °C. Pellets were dissociated with phosphate
buffered saline, and freezing and thawing steps were repeated three
times. After centrifugation, the supernatants were used as samples in
this experiment. The absorbance of the samples was measured using
anARVOMX1420Multilabel Countermicroplate reader (Perkin Elmer).
2.8. Statistical analysis
Each experiment was independently performed three ormore times
(n ≥ 3). Statistical differences were analyzed by the non-parametric
Kruskal—Wallis test followed by the Dunn's multiple comparison
test or the Steel's test for three or more group comparisons, and the
Mann–Whitney U test for pairwise comparisons. Differences were
considered signiﬁcant at P b 0.05.
3. Results
3.1. No variations among SOD1-overexpressing hESC clones
Wild-type (WT) or mutant SOD1-hESCs were established by using
the site-speciﬁc gene integration method (Sakurai et al., 2010). In our
gene-integration system, the acquisition of drug resistance indicates
that the integration of the correct gene has occurred at the hypoxan-
thine phosphoribosyltransferase 1 (HPRT1) locus. Using either two or
three drug-resistant clones with the same mutations, we examined
whether there were any variations in SOD1 gene or protein expression
among the SOD1-hESC clones. Analysis of semi-quantitative reverse
transcription polymerase chain reaction (RT-PCR) showed that all
SOD1-hESCs expressed exogenous SOD1 with no changes in endoge-
nous expression levels (Fig. 1A). These data suggest that the ectopic ex-
pression of exogenous SOD1 did not inﬂuence the endogenous
expression of the gene. Next, the SOD1 protein levels were measured
by Western blot. The expression levels of WT-, A4V- and G93A-SOD1
protein variants in SOD1-hESCs were approximately 2.0-fold higher
than that in the parent cells (Fig. 1B). The expression levels of G85R-
SOD1 (comprising the total amount of 2 bands) were almost 1.5-fold
higher than that in parent cells (Fig. 1B). Statistical analysis indicated
no signiﬁcant differences in SOD1 protein levels among clones with
the same mutations, as expected. Immunostaining showed that the
ﬂuorescence intensity of SOD1 in mutant SOD1-hESCs was higher
than that in parent cells, showing that SOD1 was overexpressed in
hESCs, but it did not form aggregates (Supplementary Fig. S1). The
enzymatic activities of SOD in WT-, A4V-, and G93A-SOD1-hESCs were
approximately 2.5-fold, 1.5-fold, and 2.5-fold higher, respectively, than
that of the parent (Fig. 1C). However, there were no statistical signiﬁ-
cant differences in the SOD activities among clones with the same
mutations. A4V-SOD1 is less stable than WT-SOD1 (Borchelt et al.,
1994). Thus, the observed fold-increase of enzymatic activity for this
variant is expected to be lower than that of WT and G93A-SOD1.
G85R-SOD1 lacks enzymatic activity due to an ion binding deﬁciency
(Hayward et al., 2002). As expected, no SOD activity above the levels
in parent cells was detected in G85R-SOD1-hESCs (Fig. 1C). The com-
bineddata show that therewere no signiﬁcant variations in SODactivity
or SOD1 protein expression levels among any of the mutant-SOD1
clones. A single clone for each mutant SOD1-hESC line was therefore
chosen for further experiments.
3.2. SOD1 overexpression did not inﬂuence the undifferentiated state of
hESCs
To assess the pluripotency of SOD1-hESCs, we examined the expres-
sion of speciﬁc markers of pluripotency by immunocytochemistry and
RT-PCR. Immunocytochemistry data indicated that all SOD1-hESC
Fig. 1. No variations in expression among SOD1-hESC clones. (A) RT-PCR analysis of exogenous and endogenous SOD1 gene expression in undifferentiated hESCs. GAPDH was used as a
loading control. Exo: exogenous-, Endo: endogenous-SOD1. (B)Quantitative analysis of SOD1protein inundifferentiatedhESCs using data obtained byWesternblot (WB). The inset shows
representative SOD1 protein WB data in undifferentiated hESCs. The asterisk indicates that G85R-SOD1 that has different mobility from that of WT-SOD1 in the WB assay (Wang et al.,
2009). β-ACTIN was used as a loading control. The expression level of SOD1 in the parent hESCs was deﬁned as 1. Values represent means ± standard deviation (SD) (n = 5).
(C) Relative enzymatic activity of SOD in undifferentiated hESCs. The activity level of SOD in the parent hESCs was deﬁned as 1. Values represent means ± SD (n = 4). P, parent hESC;
WT, wild type; A, WT-SOD1; B, A4V-SOD1; C, G85R-SOD1; D, G93A-SOD1. Numbers indicate clone identiﬁcation number.
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lines expressed pluripotencymarkers includingOCT3/4, NANOG, SSEA4,
and TRA-1-60 (Fig. 2A). RT-PCR analysis showed that the pluripotency
markers NANOG and OCT3/4 were expressed in all cell lines (Fig. 2B).
These results show that overexpression of WT and mutant SOD1 did
not affect the pluripotency of SOD1-hESCs.
SOD1-hESCs were similar to the parent hESCs in measures of cell
proliferation (Fig. 2C). All SOD1-hESCs also maintained a normal female
karyotype (46XX) with no numerical abnormalities (Fig. 2D). These
data indicate that overexpression of WT or mutant SOD1 did not affect
cell proliferation or chromosome stability.
3.3. SOD1 overexpression did not affect neural differentiation in hESCs
To determine the effects of mutant SOD1 on neural differentiation,
we generated spinal motor neurons (MNs) from hESCs as described
previously (Wada et al., 2009) (Supplementary Fig. S2A). We ﬁrst
compared the efﬁciency of MN differentiation among all SOD1-hESCs
and the parent cells (Fig. 3A). On day 10 in P2 (P2-d10), differentiated
cells contained approximately 15% OLIG2-positive MN progenitors in
all SOD1-hESCs. The rates of differentiation were not statistically
different among the parent cells and those expressing SOD1 mutants
(Fig. 3B). The proportion of OLIG2-positive MN progenitors increased
to as high as 70% on P3-d7 and decreased to 50% on P3-d14 (Fig. 3C).
During the P3 stage, there were no differences in differentiation
efﬁciency among cells. On P3-d21, all SOD1-hESCs expressed MN
markers including ISL1, HB9 and choline acetyltransferase (Fig. 3G).
The relative proportions of ISL1-positive or HB9-positive MNs were
approximately 15% and 10%, respectively (Fig. 3D). To detect the
exogenous SOD1 gene expression, RT-PCR was performed. Exogenous
SOD1 and other neuron-speciﬁc markers were detected at P2-d10, P3-
d14 and P3-d21 (Fig. 3E, F and G). These data suggest that both
WT and mutant SOD1-hESCs had similar neural differentiation
efﬁciencies compared to that of the parent cells, further indicating
that overexpression of SOD1 did not inﬂuence neuronal differentiation.
3.4. Mutant SOD1 induced morphological changes in MNs overexpressing
SOD1
Next, we assessed the inﬂuences of mutant SOD1 on MN morphol-
ogies using a separate differentiation method developed in this study
(shown in Supplementary Fig. S2B).We found no signiﬁcant differences
among cell lines with respect to the ratio in percentages of ISL1-positive
MNs to MAP2-positive neurons on d7, d14 and d21 in P4 (Fig. 4A). RT-
PCR analysis indicated that exogenous SOD1s were expressed in WT
and mutant cell lines on P4-d14 (Fig. 4B). Next, we examined three
morphological parameters, viz., soma size, the number of branches
and the longest neurite length (Supplementary Fig. S3). The expansions
of soma sizes among the cells were observed over time; no changes
were detected in the MNs derived from parental cell lines between
d14 and d21 in P4 (Fig. 4C). The number of branches in ISL1, MAP2
double-positive MNs was not different among any SOD1-hESCs or the
parent cells (Fig. 4D). Although there were no differences in soma size
or branch numbers, we found that different SOD1 mutations showed
different phenotypes with respect to the longest neurite observed in
SOD1-hESC-derived neurons. The longest neurite of ISL1, MAP2
double-positive MNs was shorter in A4V- and G93A-MNs compared to
that in the parent-MNs, but not in WT- and G85R-MNs (Fig. 4E). On
the other hand, the longest neurite of ISL1-negative, MAP2-positive
non-MNs got longer in G85R-non-MNs compared to that in the parent
cells (Fig. 4F). These data indicate that the expression of A4V- and
G93A-SOD1 only affectedMNs, whereas that of G85R-SOD1 speciﬁcally
affected non-MNs in our cellular models. The neurite length of G85R-
MNs was not altered, but the expression of G85R-SOD1 might lead to
other cellular phenotypes that we did not examine in this study.
3.5. SOD1-MNs with different mutations displayed differences in responses
to compounds
To examine whether there are the speciﬁc differences among
mutant SOD1-MNs,we treated our ALSmodel cellswith six compounds,
Fig. 2. Characterization of undifferentiated SOD1-hESCs. (A) Immunocytochemistry of the following pluripotency markers in undifferentiated SOD1-hESCs: OCT3/4, NANOG, SSEA4, and
TRA-1–60. Scale bar, 100 μm. (B) RT-PCR analysis of pluripotencymarkers in undifferentiated hESCs. GAPDHwas used as a loading control. (C) Cell proliferation of undifferentiated SOD1-
hESCs (n = 3). Fifty thousand cells were plated on a Matrigel-coated well of 96-well plates on d0. (D) Karyotype analysis in undifferentiated SOD1-hESCs.
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including drugs tested in clinical ALS trials (Glicksman, 2011) (Limpert
et al., 2013) (Lanka and Cudkowicz, 2008). We compared morphomet-
ric parameters of SOD1-MNs treated with chemicals or dimethyl
sulfoxide (DMSO) as a control. Of these compounds, riluzole is the
approved drug for ALS, and acts as a neuroprotective agent
(Bellingham, 2011; Bensimon et al., 1994). After a 4-day treatment
with 0.1 μMriluzole, only cells expressing G93A-SOD1 showed an exten-
sion of neurite length in ISL1, MAP2 double-positive MNs, while cells
Fig. 3.Motor neuron differentiation of SOD1-hESCs. (A) Immunocytochemistry of the following neural markers: OLIG2 (aMN progenitor marker; red), nestin (a neural stem cell marker;
green), TUJ1 (aneuronmarker; green), HB9 (aMNmarker; red) andMAP2 (a neuronmarker; green)duringMNdifferentiation. Cells ond10 in P2 (P2-d10), d14 in P3 (P3-d14), and d21 in
P4 (P4-d21) were stained using neural marker antibodies. Scale bar, 100 μm. (B, C, D) Quantitative analysis of neural-marker-positive cells duringMN differentiation. OLIG2-positive cells
(B and C). ISL1-positive and HB9-positive cells (D). Values representmeans± SD (n= 3). (E, F, G) RT-PCR analysis using neurons on P2-d10 (E), P3-d14 (F), and P4-d21 (G). GAPDHwas
used as a loading control. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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expressing WT-, A4V- and G93A-SOD1 showed similar effects in non-
MNs (Fig. 5A, Supplementary Table S1). Changes in soma size were
observed in MNs expressing A4V and G85R; however, there were no
signiﬁcant differences in the number of branches among any of the cell
lines (Supplementary Fig. S4A and S4B, Supplementary Table S1).
Next, we examined the cellular responses to the drugs that resulted
in neurite stabilization. The cyclic adenosine monophosphate (cAMP)
signaling pathway plays a primary role in neurite stabilization (Hannila
and Filbin, 2008). To activate this pathway, the cell-permeable cAMP
analog dibutyryl-cAMP (dbcAMP) was used. In our cellular models,
treatment with 1 mM dbcAMP increased neurite length in non-MNs
derived fromall cell lines (Fig. 5B). However, elongation of neurite length
in MNs was only observed in cells expressing A4V and G93A (Fig. 5B,
Supplementary Table S1). The soma sizes were expanded by dbcAMP
treatment in MNs from both parental cell lines and those expressing
G93A; the numbers of MN branches did not change in any of the cell
lines (Supplementary Fig. S4C and S4D, Supplementary Table S1).
To determine the effect of compounds that induce neurite out-
growth in our ALS models, we used the Rho-associated protein kinase
(ROCK) inhibitor, Y27632 (Dergham et al., 2002) (Fournier et al.,
2003). ROCK acts as amediator in growth inhibitory signaling thatmod-
ulates growth cone stability by regulating actin dynamics (Uehata et al.,
1997) (Tonges et al., 2011). In our cellular models, treatment with
10 μM Y27632 enhanced the neurite elongation of non-MNs in all cell
lines; however, amongMNs, this effect was conﬁned to lines expressing
A4V and G93A (Fig. 5C, Supplementary Table S1). Expansion in soma
Fig. 4.Morphological changes in MNs derived from SOD1-hESCs. (A) The ratio of ISL1, MAP2-double positive MNs to MAP2 positive neurons during differentiation (P4-d7, blue; P4-d14,
red; P4-d21, green). Values represent means ± SD (n = 4 to 7). (B) RT-PCR analysis of MNs on d14 in P4. GAPDH was used as a loading control. (C) Soma size (in μm2) during MN
differentiation (P4-d7, blue; P4-d14, red; P4-d21, green). The following sample sizes (n = 3 each) were counted in total: 82 to 155 neurons on P4-d7, 213 to 467 on P4-d14, and 99 to
357 on P4-d21. Black bars represent themedian value. **P b 0.01, as determined by the Kruskal–Wallis test followed by Dunn'smultiple comparison test. (D) The number ofMN branches
ond7 in P4. Values representmeans±SD (n=10), P valueswere determined by theKruskal–Wallis test followedbyDunn'smultiple comparison test. (E) The longest neurite length (μm)
of ISL1, MAP2 double-positive MNs on d7 in P4. Black bars represent the median value. The sample size was n = 3, with 153 to 185 neurons per sample counted in total. **P b 0.01, as
determined by the Kruskal–Wallis test followed by Dunn's multiple comparison test. (F) The longest neurite length (in μm) of ISL1-negative and MAP2-positive cells on d7 in P4. Black
bars represent themedian value. The sample size was n= 3, with 237 to 342 neurons per sample counted in total. *P b 0.05, **P b 0.01, as determined by the Kruskal–Wallis test followed
by Dunn's multiple comparison test. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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sizewas observed only inMNs expressingG93A; therewere no changes
in the numbers of branches in MNs following Y27632 treatment
(Supplementary Fig. S4E and S4F, Supplementary Table S1). These
data suggest that although both dbcAMP and Y27632 are effective at
inducing neurite elongation in non-MNs derived from all SOD1-hESCs,
they only have this effect on MNs expressing A4V and G93A.
Recently, kenpaullone was identiﬁed as a potential drug candidate
for the treatment of ALS disease using MNs derived from mouse ESCs
expressing G93A-SOD1 (Yang et al., 2013). This compound is effective
not only at promoting the in vitro survival of MNs expressing G93A-
SOD1, but also that of MNs with other SOD1 mutations, including
TDP43. In our cellular models, we found that the neurite length of
MNs from the parental, WT, A4V, and G85R cell lines was increased
following treatment with 5 μM kenpaullone although G93A did not
(P = 0.06) (Fig. 5D, Supplementary Table S1). In the case of non-MNs,
neurite length was only increased in cell lines expressing A4V
(Fig. 5D). In all cell lines, the MN soma sizes were expanded, but there
were no changes in the number of branches following treatment with
kenpaullone (Supplementary Fig. S4G and S4H, Supplementary
Table S1). These data indicate that kenpaullone was efﬁcacious in alter-
ing ALS phenotypes in MNs, which is consistent with Yang's results
(Yang et al., 2013).
Next, we tested MCI-186 and TRO19622, which have recently been
listed in clinical trials as drug candidates for the treatment of ALS
(Glicksman, 2011) (Limpert et al., 2013) (Lanka and Cudkowicz,
2008).MCI-186, also known as edaravone, is used for cerebral ischemia.
It was found to be effective in a mouse ALS model with the G93A-SOD1
mutation (Ito et al., 2008). Recently, edaravone was approved as an ALS
drug in Japan (www.mt-pharma.co.jp/e/release/nr/2015/pdf/e_
MTPC150626_2.pdf). In our experiments, the administration of 10 μM
MCI-186 promoted neurite elongation inMNs from cell lines expressing
G93A alone, while shortening those in non-MNs expressing G85R
(Fig. 5E, Supplementary Table S1). There were no effects on soma size
or the number of branches in any of the cell lines (Supplementary
Fig. S4I and S4J). These data suggest that effects of MCI-186 might be
limited to speciﬁc mutations in SOD1 including G93A. Next, we tested
the compound TRO19622, which failed in clinical trials (Lenglet et al.,
2014). TRO19622 was ﬁrst identiﬁed by a chemical screening assay
utilizing rat primary MNs (Bordet et al., 2007) and promoted neurite
outgrowth and survival in rat MNs in vitro (Bordet et al., 2007). Exper-
iments in vivo showed that this compound improved motor perfor-
mance, delayed the onset of the disease, and extended the life span of
G93A-SOD1 transgenic mice (Bordet et al., 2007). In our model cells,
the neurite length of MNs was promoted in the parental, A4V, and
G85R cell lines following 1 μM TRO19622 treatment (Fig. 5F, Supple-
mentary Table S1). Administration of TRO19622 did not increase the
neurite length in MNs expressing G93A (P = 0.068), but enhanced
neurite length in non-MNs from A4V and parental cell lines. Soma size
decreased in MNs from both in WT and parental cell lines, while the
branch numbers decreased in MNs from the parental and G93A cell
lines (Supplementary Fig. S4K and S4L, Supplementary Table S1).
These data suggest that TRO19622 may also be effective at treating
ALS phenotypes in MNs with speciﬁc SOD1 mutations.
Furthermore, in order to investigate drug responses, we performed
dose–response assays using riluzole and MCI-186. Riluzole at a concen-
tration of 100 nMwas effective in G93A-MNs, while a lower concentra-
tion (10 nM alone) was efﬁcacious in A4V-MNs to enhance neurite
length (Fig. 6A). Higher concentrations of riluzole did not affect neurite
length ofMNs in our ALSmodels. These results suggest that the effective
concentration of riluzole might be dependent on SOD1 mutation types.
On the other hand, MCI-186 enhanced the neurite length in G93A-MNs
at both 10 and 100 μM(Fig. 6B). This compoundwas not effective in the
parent and other mutation types of SOD1-MNs at the concentrations
examined. Collectively, the results of the dose–response assays indicat-
ed that ALS models expressing different SOD1 mutations displayed
differential responses to ALS drugs.
Fig. 5.Drug responses inMNs derived fromSOD1-hESCs.Drug treatmentswere carried out fromd3 to d7 in stage P4 cells.Measurement of the longest neurite length of ISL1,MAP2double-
positive (ISL1+), or ISL1-negative,MAP2-positive neurons (ISL1-) on d7 in P4was determined for cells receiving the following treatments (n=3 each): (A) riluzole (0.1 μM), (B) dbcAMP
(1mM), (C) Y27632 (10 μM), (D) kenpaullone (5 μM), (E)MCI-186 (10 μM), and (F) TRO19622 (1 μM). *P b 0.05, **P b 0.01, as determined by theMann–Whitney U test. Treatment with
dimethyl sulfoxide (DMSO) as a control,−; treatment with compounds, +. The experiments using riluzole (A), dbcAMP (B) and Y27632 (C) were carried out simultaneously; therefore
comparisons among the control data using DMSO were the same for these experiments.
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4. Discussion
It is known that mutation types of SOD1 affect not only enzymatic
activity and protein half-life of SOD1, but also age at onset and the
survival time of SOD1-ALS patients (Hayward et al., 2002) (Borchelt
et al., 1994) (Regal et al., 2006). However, there are very few studies
focusing on comparative study of SOD1 mutations. Here, we generated
SOD1-ALS models derived from mutant SOD1-overexpressing hESCs
with identical genetic background and we found mutation-speciﬁc
morphological alterations. Furthermore, our models revealed that
mutation types affect drug responses.
Recently, two papers reported that mutant SOD1s inﬂuenced not
only cell death but also the morphologies such as soma size, neurite
length and abnormal organelles in MNs derived from the patient-
speciﬁc iPSCs (Chen et al., 2014; Kiskinis et al., 2014). Although cell
death was not detected in our ALS models, the reduction of neurite
length, which could be a cellular disease phenotype, was observed in
our ALS models except in G85R-SOD1. Morphological changes, primar-
ily the elongation of MN neurite length, were detected following
treatment with the compounds we investigated. Atrophic changes or
axonopathy of MNs is observed in ALS (Ferraiuolo et al., 2011; Fischer
et al., 2004; Vinsant et al., 2013); hence, the MN neurite length change
of our ALS models might be a good predictor of drug efﬁcacy in
ALS. Our ALS models have potential as cell materials for cell-based
high-throughput drug screening, similar to previous studies using
patient-iPSCs (Egawa et al., 2012) (Yang et al., 2013).
Interestingly, the cellular phenotype could also be classiﬁed by
differences in SOD1-mutation-dependent responses to the same
compound. Since our models have an identical genetic background,
these differential responses were caused by differences in SOD1 muta-
tions. Therefore, our ALS models are promising tools for investigating
the role and toxicity of mutant SOD1 on disease onset and progression
as well as differential drug responses.
Results from this study suggest that mutant-speciﬁc experimental
and clinical strategies may be required for drug discovery and clinical
trials. However, it is unclear how much individual genetic background
affects mutant-speciﬁc strategies. In addition, gene overexpression
approach has limitations such as unnatural gene expression and limited
Fig. 6.Dose–response of ALS drugs inMNs derived from SOD1-hESCs. Drug treatments were carried out from d3 to d7 in stage P4 cells. Measurement of the longest neurite length of ISL1,
MAP2double-positiveMNswasdone. DMSOwasused as a controlwithoutdrug treatment. (A) The concentrations of riluzolewere 10, 100 and1000 nM(n=4). (B) The concentrations of
MCI-186 were 1, 10 and100 μM (n= 3). *P b 0.05, **P b 0.01, as determined by the Steel's test. Red bars represent the median value. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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applicability. In fact, we haven't established any mutant TDP43-
expresssing hESC lines by our gene integration system (data not
shown). Future research on drug response-based classiﬁcation using
SOD1-ALS patient-derived iPSCs with different genetic background
might be interesting and worthwhile.
Riluzole, which is widely used and the approved drug for ALS,
showed effects on A4V- and G93A-MNs at a single concentration of 10
and 100 nM, respectively, in our models. It is unclear why the drug
was effective at a single dose but not in a dose-dependent manner
in this study. This drug was reported to provide protective effects to
primary rat MNs treated with media conditioned from primary
astrocytes derived from mouse ALS models (including G93A and G86R
SOD1 variants) (Rojas et al., 2014). Similarly, MCI-186, which is
known as a neuroprotective drug (Shichinohe et al., 2004), only affected
the elongation of neurites in MNs expressing G93A-SOD1. These results
suggest that neuroprotective drugs might be effective at treating ALS
phenotypes with respect to non-cell-autonomous toxicity or speciﬁc
types of SOD1 mutations.
Mutant SOD1 variants are divided into two classes on the basis of the
metal ion content and the position of the mutation: WT-like mutants
and metal-binding region (MBR) mutants (Rodriguez et al., 2002;
Tiwari and Hayward, 2005). A4V and G93A are WT-like mutants,
whereas G85R is a MBR mutant. We found that dbcAMP and Y27632
showed efﬁcacy in non-MNs from all mutant-SOD1, WT-SOD1, and
parental cell lines examined. However, they were only effective in
MNs from cell lines expressing SOD1 variants in the WT-like mutant
group. In contrast, kenpaullone was not effective at increasing the
longest neurite length in non-MNs, but was widely effective in MNs,
regardless of mutation type (although the effects on MNs expressing
G93A were not statistically signiﬁcant). TRO19622 showed effective-
ness similar to kenpaullone despite the fact that the targets of these
two compounds are different: TRO19622 inhibits the mitochondrial
permeability transition pore complex (Bordet et al., 2007), while
kenpaullone inhibits glycogen synthase kinase 3 and some cyclin-
dependent kinases (Martinez et al., 2002; Senderowicz and Sausville,
2000).
In this study, out of over 100 SOD1 mutants, only three SOD1
mutants were examined. By using SOD1-ALS models with a large
number of other mutation types, SOD1 mutations could be potentially
classiﬁed into drug response-based categories. Astrocytes are addition-
ally implicated in MN death by secretion of neurotoxic factors (Wada
et al., 2012) (Yamanaka et al., 2008) (Re et al., 2014) (Rojas et al.,
2014) (Nagai et al., 2007). To the best of our knowledge, there are no
reports that astrocytes show SOD1 mutation-dependent responses to
drug in a manner similar to MNs. Future research should address
questions regarding the classiﬁcation of ALS into treatment-responsive
categories and the associated role of astrocytes.
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